| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2016 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 7,000 | $12.02 | $84,146.00 | -3.1% | |
| Aug 5, 2016 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 392,000 | $61.81 | $24,231,095.79 | -15.5% | |
| Jul 29, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $82.94 | $17,001,880.00 | -0.2% | |
| Jul 28, 2016 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,213 | $83.16 | $100,873.08 | -48.3% | |
| Jul 28, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 240,000 | $82.87 | $19,888,567.93 | - | |
| Jul 26, 2016 | JNJ Johnson & Johnson | Caruso Dominic J | Exec VP, Finance; CFO | Sell | 41,146 | $125.01 | $5,143,809.59 | -26.1% | |
| Jul 22, 2016 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 2,935 | $125.01 | $366,895.55 | -10.2% | |
| Jul 18, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 2,297 | $17.76 | $40,794.72 | -3.4% | |
| Jul 14, 2016 | SUPN Supernus Pharmaceuticals, Inc. | Patrick Gregory S | VP, Chief Financial Officer | Sell | 3,395 | $22.00 | $74,690.00 | -37.7% | |
| Jul 12, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $79.54 | $16,703,820.00 | -0.2% | |
| Jul 7, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 225,000 | $79.14 | $17,806,358.12 | - | |
| Jul 6, 2016 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 1,980 | $7.48 | $14,818.52 | -6.3% | |
| Jul 6, 2016 | ESPR Esperion Therapeutics, Inc. | McGovern Mark E | Director | Buy | 5,000 | $10.00 | $50,000.00 | +833.3% | |
| Jul 5, 2016 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,402 | $7.47 | $10,468.03 | -1.9% | |
| Jul 5, 2016 | MRK Merck & Co., Inc. | Graddick Weir Mirian M | Exe V-p, Hr | Sell | 45,000 | $57.99 | $2,609,329.50 | -17.6% | |
| Jul 5, 2016 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,557 | $7.47 | $11,625.34 | -1.8% | |
| Jul 5, 2016 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 60,000 | $58.00 | $3,480,000.00 | -5.4% | |
| Jul 1, 2016 | MRK Merck & Co., Inc. | Graddick Weir Mirian M | Exe V-p, Hr | Sell | 30,000 | $57.49 | $1,724,553.00 | -18.5% | |
| Jul 1, 2016 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 50,000 | $57.69 | $2,884,415.00 | -100% | |
| Jun 30, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 215,000 | $78.46 | $16,869,941.90 | - | |
| Jun 30, 2016 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 36,950 | $2.22 | $82,158.50 | +286.4% | |
| Jun 29, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $77.86 | $17,129,162.59 | - | |
| Jun 28, 2016 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Vice President | Buy | 1,452 | $13.68 | $19,863.36 | +31.6% | |
| Jun 24, 2016 | SCYX Scynexis Inc | MacHado Clarence Patrick | Director | Buy | 20,000 | $2.39 | $47,800.00 | New | |
| Jun 24, 2016 | SCYX Scynexis Inc | MacDonald Guy | Director | Buy | 40,000 | $2.39 | $95,600.00 | New |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.